INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for potential securities fraud and unlawful business practices following disappointing trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by Pomerantz LLP, which is known for its expertise in corporate and securities class litigation [5]. - Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Company Performance - On September 28, 2025, MoonLake reported unsatisfactory results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest improvements compared to placebo [4]. - Following the announcement of these results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [4].